ST elevation acute myocardial infarction
Conditions
Interventions
Experimental group:Conventional treatment + Jiuxin pill
Control group:Conventional treatment + Jiuxin pill simulator
Sponsors
The First Affiliated Hospital of Henan University of Chinese Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: Subjects must meet all of the following inclusion criteria to be eligible for the study: (1) 18 years old to 75 years old; (2) Those with infarct chest pain within 24 hours and who have undergone emergency PCI surgery; (3) ST segment elevation of =0.2mV in two or more adjacent leads on the electrocardiogram or new left bundle branch block; (4) Those who meet the TCM diagnostic criteria for acute myocardial infarction (syndrome of phlegm turbidity and blood stasis blocking heart meridian); (5) Voluntarily participate in this study and sign the informed consent form.
Exclusion criteria
Exclusion criteria: Subjects must be excluded from this trial if they meet any of the following criteria: (1)Those who have been in a critical condition due to STEMI; (2)Those who perform long-duration (more than 20 minutes) cardiopulmonary resuscitation; (3)Those with suspected aortic dissection or acute pulmonary embolism; (4)Those with definite mechanical complications (including ventricular septal perforation or rupture of the papillary tendon bundle or ongoing or already ruptured free left ventricular wall); (5)Those with severe cardiogenic shock and no response to antihypertensive drugs; (6)Patients with uncontrolled pulmonary edema due to acute left heart failure; (7)Patients with malignant arrhythmia that is difficult to be controlled by medication; (8)Those who have a history of major bleeding in the cerebral blood vessels gastrointestinal tract respiratory tract urinary tract or other organs within the past month; (9)Those who still have active bleeding in any part (including menstruation); (10)Those with a known bleeding constitution or severe hemostasis and coagulation disorders; (11)Those who are currently using therapeutic doses of anticoagulants (such as warfarin or new anticoagulants); (12)Patients with severe liver and kidney dysfunction [ALT=5ULN(Upper Limit of Normal)Cr>134µmol/L(2mg/dl)or eGFR<45ml/min/1.73m2]; (13)Those with severe chronic obstructive pulmonary disease (COPD) or respiratory failure; (14)Severely infected individuals; (15)Severely weak individuals such as those with cachexia; (16)Patients with severe mental illness; (17)Those with malignant tumors; (18)Those with other diseases and an expected survival period of less than one year; (19)Those who are allergic to the drug components of the study; (20)Pregnant or lactating women; (21)Patients who are currently participating in other clinical studies; (22)Those who the researchers consider unsuitable to participate in the trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Major cardiovascular and cerebrovascular events; | — |
Secondary
| Measure | Time frame |
|---|---|
| CCS angina Scale and Seattle Angina Scale;Markers of myocardial injury;The incidence of STEMI serious complications;The incidence of severe bleeding;TCM syndrome score;Inflammation-related indicators;Cardiac color ultrasound;Coronary blood flow grading after PCI;N-Terminal Pro-Brain Natriuretic Peptide(NT-proBNP); | — |
Countries
China
Contacts
Public Contactzhumingjun
The First Affiliated Hospital of Henan University of Chinese Medicine
Outcome results
None listed